Drug intelligence / Profile preview

ICH-1 (Guangzhou University of Chinese Medicine)

Development stage: Preclinical
Lead developer: Guangzhou University of Chinese Medicine
Administration: Oral

Overview

**ICH-1** is an investigational eight-herb traditional Chinese medicine formula developed for acute intracerebral hemorrhage. It includes the blood-activating and stasis-dispersing components **Hirudo** and **Tabanus** and was evaluated versus placebo and the related six-herb ICH-2 formula in the CRRICH randomized trial. In patients treated within 6 hours of symptom onset, ICH-1 did not significantly improve clinical outcomes and was associated with increased bleeding risk, plausibly related to its blood-activating herbal components. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6528012/))

Targets

F2 (Thrombin)

Beyond the preview

Go deeper on ICH-1 (Guangzhou University of Chinese Medicine).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ICH-1 (Guangzhou University of Chinese Medicine).

Explore the full profile